Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03494569 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03494569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03494569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Suspended
Start date
July 6, 2018
Completion date
September 7, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphoblastic leukemia in remission, acute myeloid leukemia, acute myeloid leukemia in remission, hematopoietic cell transplantation recipient, minimal residual disease, myelodysplastic syndrome, secondary acute myeloid leukemia